A Call for a Better PoPH Risk Assessment Model, and Treatment Direction

4 August 2025

Yu Kuang Lai

https://doi.org/10.1002/pul2.70147

Abstract

Dear Editor,
The article, “Survival Outcomes and Impact of Targeted PAH Therapy in Portopulmonary Hypertension in the PVRI GoDeep Meta-Registry” by Jose et al. addresses the controversial question on the survival benefit of PAH drugs in portopulmonary hypertension (PoPH) [1]. Treatment strategies in PoPH are often extrapolated from other PAH subtypes as PoPH have largely been excluded from large PAH drug randomized trials. In this context, the present study represents an important contribution to the management of PoPH.

Read the full letter to the editor

Share: